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Objectives This study sought to evaluate the relative safety and efficacy of fondaparinux and enoxaparin in patients with
acute coronary syndromes (ACS) treated with glycoprotein (GP) IIb/IIIa inhibitors or thienopyridines.
Background The OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial showed that fondaparinux reduced
major bleeding by 50% compared with enoxaparin while preserving similar efficacy. Whether this benefit is consistent
in the presence or absence of concurrent antiplatelet therapy with clopidogrel and GP IIb/IIIa inhibitors is unknown.
Methods Patients with ACS (n  20,078) were randomized as a part of the OASIS 5 trial to receive either fondaparinux or
enoxaparin. The use of GP IIb/IIIa inhibitors or thienopyridines was at the discretion of the treating physician. A Cox
proportional hazard model was used to compare outcomes.
Results Of the 20,078 patients randomized, 3,630 patients received GP IIb/IIIa and 13,531 received thienopyridines. There was a
40% reduction in major bleeding with fondaparinux compared with enoxaparin in those treated with GP IIb/IIIa (5.2% vs.
8.3%, hazard ratio [HR]: 0.61, p 0.001). A similar reduction was found in those treated with thienopyridines (3.4% vs.
5.4%, HR: 0.62, p 0.001). Ischemic events were similar between the groups, resulting in a superior net clinical outcome
(death, myocardial infarction, refractory ischemia, or major bleeding) favoring fondaparinux (GP IIb/IIIa subgroup 14.8% vs.
18.9%, HR: 0.77, p 0.001 and thienopyridines subgroup 11.0% vs. 13.2%, HR: 0.82, p 0.001).
Conclusions In patients receiving GP IIb/IIIa inhibitors or thienopyridines, fondaparinux reduces major bleeding and improves net
clinical outcome compared with enoxaparin. (J Am Coll Cardiol 2009;54:468–76) © 2009 by the American College
of Cardiology Foundation
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July 28, 2009:468–76 Fondaparinux Versus Enoxaparin With GP IIb/IIIantiplatelet therapy with either glycoprotein (GP) IIb/IIIa
nhibitors or thienopyridines reduces ischemic events at the
ost of an increase in bleeding in patients with acute
oronary syndromes (1,2). The American College of Car-
iology and American Heart Association as well as the
uropean Society of Cardiology guidelines recommend
arly treatment with either clopidogrel or intravenous GP
Ib/IIIa inhibitors (3,4). Major bleeding has been shown
epeatedly in observational analyses to be associated with an
ncreased risk of death (5–7). As a result, it is important to
etermine the risk of bleeding of novel antithrombotic
gents when combined with these potent antiplatelet agents
ompared with standard therapies.
Fondaparinux is a synthetic factor Xa inhibitor (Arixtra,
laxoSmithKline, Brentford, United Kingdom) that selec-
ively binds antithrombin and potentiates neutralization of
actor Xa. The OASIS 5 (Fifth Organization to Assess
trategies in Ischemic Syndromes) trial demonstrated that
ondaparinux compared with enoxaparin reduced major
leeding by 50% and mortality by 17% in over 20,000
atients with non–ST-segment elevation (NSTE) (8).
The objective of this analysis was to determine the
fficacy, safety, and net clinical outcome of fondaparinux
ersus enoxaparin in patients with NSTE-acute coronary
yndrome (ACS) treated with: 1) a GP IIb/IIIa inhibitor;
nd 2) thienopyridines.
ethods
atients. The OASIS 5 trial briefly enrolled 20,078 pa-
ients with NSTE-ACS and randomized them to fondapa-
inux 2.5 mg subcutaneously once daily or enoxaparin 1
g/kg of body weight subcutaneously twice daily in a
ouble-blind fashion (8). Patients were eligible if they had
ad ischemic symptoms within 24 h and at least 2 of the 3
ollowing criteria: an age of at least 60 years, an elevated
evel of troponin or creatine kinase-myocardial band (CK-
B) isoenzyme, or electrocardiographic changes indicative
f ischemia. In the fondaparinux arm, patients were treated
ith fondaparinux for up to 8 days or until hospital
ischarge, whichever came first. In the enoxaparin arm,
atients were treated with enoxaparin for 2 to 8 days until
he patient was deemed clinically stable. The use of GP
Ib/IIIa inhibitors or thienopyridines was left to the discre-
ion of the treating physician.
utcomes. Efficacy was assessed by evaluating rates of the
omposite of death, myocardial infarction (MI), and refrac-
ory ischemia at 30 days. Safety was assessed by evaluating
ates of major bleeding, and net clinical outcome was
ssessed evaluating rates of the composite of death, MI,
efractory ischemia, or major bleeding at 30 days.
MI was defined as the following: in those without
revious infarction within 7 days, as prolonged ischemic
ymptoms with cardiac enzyme elevation (troponin or CK-B) of 2 upper limit of normal, electrocardiographic Ihanges indicative of ischemia or
waves or pathologic evidence
f acute MI (9). In those who
resented with an MI at baseline,
new MI within 24 h was de-
ned as 20 min of ischemic
ymptoms with either new ST-
egment elevation or depression.
n those who presented with an
I at baseline, a new MI within
4 h to 7 days was defined as
schemic symptoms 20 min
ith 1 of the following: 1) typical
ise and fall of cardiac biomarker
evels (including troponin, CK-MB)
o at least 2 upper limit of
ormal (if markers are already
levated, then 50% increase in
nzymes required); 2) new ST-segment elevation or depres-
ion; or 3) new Q waves in 2 contiguous leads. Within 48 h
f percutaneous coronary intervention (PCI), a new MI was
efined as CK-MB 3 the upper limit of normal (50%
ncrease required if elevated) or new ST-segment elevation
r development of new Q waves. Similarly, within 48 h of
oronary artery bypass surgery, a new MI was defined as a
K-MB 5 upper limit of normal or new Q waves in 2
ontiguous leads.
The definition of major bleeding was any clinically overt
leeding that was either fatal, intracranial bleeding, retro-
eritoneal, intraocular leading to significant visual loss,
equiring 2 U of blood transfused, or associated with a
ecrease of hemoglobin 3 g/dl (with each unit of trans-
used blood counting for 1.0 g/dl).
tatistical analysis. Patients were stratified into subgroups
hat received GP IIb/IIIa inhibitors and the subgroup that
id not. Patients were also stratified into subgroups that
eceived thienopyridines in the hospital and those that did
ot. Baseline characteristics were compared using the chi-
quare test for proportions and Student t test for continuous
ariables.
A Cox proportional hazards model was used to compare
fficacy (death, MI, or refractory ischemia) as well as major
leeding and net clinical outcome in the fondaparinux
ersus enoxaparin groups in: 1) those that received GP
Ib/IIIa inhibitors; 2) those that received thienopyridines;
nd 3) those that received both agents. This analysis was
epeated in the PCI subgroup in those that received GP
Ib/IIIa inhibitors, those that received thienopyridines at
east 6 h before PCI, and both. In the PCI subgroup,
utcomes by type of GP IIb/IIIa inhibitor and loading dose
f clopidogrel were compared between the fondaparinux
nd enoxaparin groups. Statistical significance was defined
s a p  0.05 and for interaction tests p  0.10.
A propensity score was developed for the use of GP
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CI  confidence interval
CK-MB  creatine kinase-
myocardial band
GP  glycoprotein
HR  hazard ratio
MI  myocardial infarction
NSTE  non–ST-segment
elevation
OR  odds ratio
PCI  percutaneous
coronary intervention
RR  relative riskIb/IIIa inhibitors and included variables that influenced the
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Fondaparinux Versus Enoxaparin With GP IIb/IIIa July 28, 2009:468–76se of GP IIb/IIIa inhibitors such as age, sex, diabetes,
T-segment deviation, and elevated cardiac enzymes and
ther baseline variables. The propensity score was used to
djust the Cox proportional hazards model to compare
utcomes in the fondaparinux versus enoxaparin groups by
se of GP IIb/IIIa. A second propensity score for the use of
hienopyridines was developed similarly to adjust the Cox
roportional hazard model comparing the fondaparinux
ersus enoxaparin groups by use of thienopyridines.
esults
n the OASIS 5 trial, of the 20,078 patients with acute
oronary syndromes that were enrolled, 3,630 patients
18%) received a GP IIb/IIIa inhibitor, 13,532 patients
67%) received a thienopyridine, and 13,916 patients (69%)
eceived either a thienopyridine or GP IIb/IIIa inhibitor in
he hospital.
P IIb/IIIa inhibitors. Baseline characteristics of patients
ho received a GP IIb/IIIa inhibitor are compared with
hose who did not receive one in Table 1. Patients treated
ith GP IIb/IIIa inhibitors were younger, were a higher
Baseline Characteristics for Patients Treated WTable 1 Baseline Characteristics for Patient
Characteristic
G
Geographic region
North America
Latin America
Western Europe
Eastern Europe
Australia
South Africa
Asia
Age (mean)
Age 75 yrs
Male sex
Prior MI
Diabetic
Prior coronary bypass surgery
Prior PCI
Troponin/CK-MB ULN
ST-segment depression 1 mm
Transient ST-segment elevation 2 mm
T-wave inversion (2 mm)
Medications after randomization
Aspirin
Clopidogrel
Beta-blocker
ACE inhibitor
Statin
Intravenous heparin
Revascularization during initial hospitalization
PCI
Coronary bypass surgery
*Data are presented as n (%). The p value refers to difference in use
ACE  angiotensin-converting enzyme; CK-MB  creatine kinase myoca
percutaneous coronary intervention; ULN  upper limit of normal.roportion of male subjects, and had elevated cardiac
nzymes. For geographic variation, the highest rate of GP
Ib/IIIa use was in North America and Western Europe, and
he lowest rates were in Asia and Eastern Europe (Table 1).
In those treated with GP IIb/IIIa inhibitors, fondapa-
inux had similar rates of death, MI, or refractory ischemia
t 30 days as enoxaparin (11.8% vs. 13.2%, unadjusted
azard ratio [HR]: 0.89, 95% confidence interval [CI]: 0.74
o 1.07, p  0.20, and adjusted HR: 0.87, 95% CI: 0.72 to
.06, p  0.16) (Table 2) (Fig. 1). In those not treated with
P IIb/IIIa inhibitors, there were similar rates of death,
I, or refractory ischemia between fondaparinux and enox-
parin, (7.1% and 7.7%, unadjusted HR: 0.93, 95% CI: 0.83
o 1.04, p  0.23, and adjusted HR: 0.93, 95% CI: 0.82 to
.04, p  0.19, interaction p  0.63).
In those treated with GP IIb/IIIa inhibitors, there was a
0% reduction in major bleeding with fondaparinux versus
noxaparin at 30 days (5.2% vs. 8.3% respectively, unad-
usted HR: 0.61, 95% CI: 0.47 to 0.79, p  0.001, and
djusted HR: 0.60, 95% CI: 0.46 to 0.78, p 0.001) (Fig. 2).
n those not treated with GP IIb/IIIa inhibitors, there was
nd Without GP IIb/IIIa Inhibitorsated With and Without GP IIb/IIIa Inhibitors
IIIa Use
,630)
No GP IIb/IIIa Use
(n  16,448) p Value
(39) 1,309 (61) 0.001*
(10) 1,738 (90)
(29) 4,952 (71)
(5) 6,477 (95)
(27) 384 (73)
(8) 181 (92)
(5) 1,407 (95)
67 0.001
(20) 4,297 (26) 0.001
(71) 9,788 (60) 0.001
(22) 4,377 (27) 0.001
(25) 4,165 (25) 0.83
(10) 1,267 (8) 0.001
(15) 1,786 (11) 0.001
(85) 11,041 (67) 0.001
(43) 8,688 (53) 0.001
(9) 820 (5) 0.001
(21) 4,235 (26) 0.001
(99) 16,000 (97) 0.001
(87) 9,351 (57) 0.001
(88) 14,348 (87) 0.049
(67) 11,636 (71) 0.001
(86) 12,541 (76) 0.001
(23) 1,988 (12) 0.001
(71) 4,297 (26) 0.001
(10) 1,495 (9) 0.06
b/IIIa inhibitor between the different geographic regions.ith as Tre
P IIb/
(n  3
853
189
2,058
306
139
15
70
65
737
2,591
787
913
376
546
3,097
1,554
333
754
3,576
3,159
3,210
2,427
3,121
833
2,592
367
of GP II
rdial band; GP  glycoprotein; MI  myocardial infarction; PCI 
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July 28, 2009:468–76 Fondaparinux Versus Enoxaparin With GP IIb/IIIalso a 40% reduction in major bleeding with fondaparinux
ompared with enoxaparin (2.7% vs. 4.3%, respectively,
nadjusted HR: 0.62, 95% CI: 0.53 to 0.74, p  0.001, and
djusted HR: 0.62, 95% CI: 0.52 to 0.73, p  0.001,
nteraction p  0.86). In terms of net clinical outcome
composite of death, MI, refractory ischemia, or major
leeding) at 30 days, there was a consistent benefit for
ondaparinux for those treated with GP IIb/IIIa inhibitors
eath, MI, Refractory Ischemia, Major Bleeding, and Net Clinicalutcome at 30 Days in Those Treated With a GP IIb/IIIa InhibitoTable 2 Death, M , Refractory Ischemia, M jor Bleeding, a d NetOutcome at 30 Days in Those Treated With a GP IIb
Outcome
GP IIb/IIIa Use
(n)
Fondaparinux
(%)
E
Death, MI, refractory ischemia Yes (3,630) 220 (11.8) 2
No (16,448) 585 (7.1) 6
Death Yes (3,630) 58 (3.1)
No (16,448) 237 (2.9) 2
MI Yes (3,630) 118 (6.4) 1
No (16,448) 269 (3.3) 2
Major bleeding Yes (3,630) 96 (5.2) 1
No (16,448) 218 (2.7) 3
Net clinical outcome† Yes (3,630) 278 (14.9) 3
No (16,448) 748 (9.1) 9
Interaction p value for unadjusted analysis. †Net clinical outcome is defined as composite of de
CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.
Figure 1 Safety and Efficacy of Fondaparinux Versus Enoxapari
Fondaparinux reduced major bleeding and improved net clinical outcome compared
with enoxaparin irrespective of glycoprotein (GP) IIb/IIIa or thienopyridine use. CI 14.9% vs. 18.9%, unadjusted HR: 0.77, 95% CI: 0.66 to
.90, p  0.001, and adjusted HR: 0.76, 95% CI: 0.65 to
.90, p  0.001) as well those not treated with GP IIb/IIIa
9.1% vs. 11.0%, unadjusted HR: 0.83, 95% CI: 0.75 to
.91, p  0.001, and adjusted HR: 0.81, 95% CI: 0.65 to
.90, p  0.001, interaction p  0.42).
For the PCI subgroup, there were similar rates of death,
I, and refractory ischemia in both the fondaparinux and
ical
Inhibitor
arin Unadjusted HR
(95% CI)
Adjusted HR
(95% CI) Interaction p Value*
3.2) 0.89 (0.74–1.07) 0.87 (0.72–1.06) 0.63
.7) 0.93 (0.83–1.04) 0.93 (0.82–1.04)
.6) 0.85 (0.60–1.22) 0.85 (0.59–1.23) 0.89
.5) 0.83 (0.70–0.98) 0.79 (0.66–0.95)
.4) 0.86 (0.67–1.10) 0.83 (0.64–1.07) 0.46
.5) 0.96 (0.81–1.14) 0.99 (0.83–1.17)
.3) 0.61 (0.47–0.79) 0.60 (0.46–0.78) 0.86
.3) 0.62 (0.53–0.74) 0.62 (0.52–0.73)
8.9) 0.77 (0.66–0.90) 0.76 (0.65–0.90) 0.42
1.0) 0.83 (0.75–0.91) 0.81 (0.74–0.90)
refractory ischemia, or major bleeding.
P IIb/IIIa and Thienopyridine Subgroups
dence interval; MI  myocardial infarction.rClin
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Fondaparinux Versus Enoxaparin With GP IIb/IIIa July 28, 2009:468–76he enoxaparin groups, regardless of GP IIb/IIIa use (Fig. 3).
here were consistent benefits in terms of major bleeding of
ondaparinux compared with enoxaparin in the PCI popula-
ion in both those treated and not treated with GP IIb/IIIa
nhibitors (Fig. 3). In terms of net clinical outcome, there was
rend for a reduction in events in the PCI populations in those
reated with GP IIb/IIIa with fondaparinux versus enoxaparin
p  0.05) (Fig. 3). The outcomes by type of GP IIb/IIIa
nhibitor during PCI are shown in Table 3.
Up-front GP IIb/IIIa inhibitors for patients undergo-
ng PCI (excludes bailout treatment after PCI started)
id not seem to be protective against catheter thrombus
n both the fondaparinux (0.7% [15 of 2,028] not
eceiving up-front GP IIb/IIIa vs. 1.3% [14 of 1,077]
eceiving up-front GP IIb/IIIa, p  0.12) and enoxaparin
roups (0.3% [5 of 1,987] not receiving up-front GP
Ib/IIIa vs. 0.3% [3 of 1,085] receiving up-front GP
Ib/IIIa, p  0.90).
hienopyridines. As shown in Table 4, 13,532 patients
67%) received thienopyridines versus 6,546 (33%) patients
ot treated with thienopyridines in the hospital. Patients
reated with thienopyridines were slightly younger and more
ikely to be male and to have elevated cardiac enzyme levels.
Figure 2 Kaplan-Meier Event Curves for Major Bleeding and Ne
Net clinical outcome (death, myocardial infarction, refractory ischemia, or major blatients treated with thienopyridines were more likely to (ave been treated with statins, unfractionated heparin, and
CI in the hospital (Table 4). The highest rate of thien-
pyridine use was in Asia and North America, and the
owest rate was in Eastern Europe (Table 4).
For the composite of death, MI, or refractory ischemia,
ondaparinux had similar efficacy compared with enoxaparin
n both those treated with thienopyridines (8.6% vs. 9.1%,
espectively, unadjusted HR: 0.94, 95% CI: 0.84 to 1.05,
 0.20, and adjusted HR: 0.94, 95% CI: 0.84 to 1.06,
 0.29) and those not (6.7% vs. 7.5%, respectively,
nadjusted HR: 0.89, 95% CI: 0.74 to 1.07, p  0.21, and
djusted HR: 0.87, 95% CI: 0.72 to 1.05, interaction p 
.61) (Table 5) (Fig. 1).
In terms of safety, fondaparinux was associated with a
0% reduction in major bleeding at 30 days in both the
ubgroup treated with thienopyridines (3.4% vs. 5.4%,
espectively, unadjusted HR: 0.62, 95% CI: 0.53 to 0.73,
 0.001, and adjusted HR: 0.62, 95% CI: 0.52 to 0.73,
 0.001) and the subgroup not treated with thienopy-
idines (2.6% vs. 4.2%, unadjusted HR: 0.63, 95% CI:
.48 to 0.83, p  0.001, and adjusted HR: 0.62, 95% CI:
.47 to 0.83, p  0.001, interaction p  0.92) (Fig. 2)
ical Outcome for GP IIb/IIIa and Thienopyridine Subgroups
). GP  glycoprotein; HR  hazard ratio.t Clin
eedingTable 5).
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July 28, 2009:468–76 Fondaparinux Versus Enoxaparin With GP IIb/IIIaWith regard to net clinical outcome at 30 days (death,
I, refractory ischemia, or major bleeding), fondaparinux
as associated with a 20% reduction in both the subgroup
reated with thienopyridines (11.0% vs. 13.2%, unadjusted
R: 0.82, 95% CI: 0.75 to 0.91, p  0.001, and adjusted
R: 0.82, 95% CI: 0.74 to 0.90, p  0.001) and those not
reated with thienopyridines (8.5% vs. 10.6%, unadjusted
Figure 3 In Those Undergoing PCI, the Efficacy and Safety of F
Those Treated With GP IIb/IIIa Inhibitors or Pre-Tre
In the PCI population, fondaparinux reduced major bleeding compared with enoxap
of GP IIb/IIIa or thienopyridine pre-treatment. PCI  percutaneous coronary interve
Death, MI, or Refractory Ischemia or Major BleeUndergoing PCI by Loading Dose of ClopidogrelTable 3 Death, MI, or Refract ry Ischemia oUndergoing PCI by Loading Dose of
Outcome Fonda
Death, MI, or refractory ischemia
Tirofiban (n  1,102) 6
Eptifibatide (n  773) 3
Abciximab (n  686) 6
Clopidogrel loading dose 300 mg (n  2,977) 15
Clopidogrel loading dose 600 mg (n  145)
Major bleeding
Tirofiban (n  1,102) 2
Eptifibatide (n  773)
Abciximab (n  686) 1
Clopidogrel loading dose 300 mg (n  2,977) 4
Clopidogrel loading dose 600 mg (n  145)*Interaction p values are nonsignificant for these subgroups (p  0.05).
Abbreviations as in Table 2.R: 0.80, 95% CI: 0.68 to 0.93, p  0.001, and adjusted
R: 0.78, 95% CI: 0.66 to 0.92, p 0.003, interaction p
.78) (Table 5).
For those patients undergoing PCI during the initial
ospitalization, there were similar rates of death, MI, and
efractory ischemia in both the fondaparinux and enoxapa-
in groups at 30 days, regardless of whether thienopyridines
parinux Versus Enoxaparin in
(>6 h) With Thienopyridines or Both
gardless
other abbreviations as in Figure 1.
in Patientspe of GP IIb/IIIa Inhibitorjor Ble ding in Patients
idogrel or Type of GP IIb/IIIa Inhibitor
x (%) Enoxaparin (%) Unadjusted HR (95% CI)*
2) 70 (12.8) 0.87 (0.62–1.22)
) 31 (7.9) 1.15 (0.71–1.87)
6) 42 (12.9) 1.32 (0.89–1.96)
4) 143 (9.6) 1.09 (0.87–1.37)
) 5 (6.5) 1.40 (0.43–4.58)
) 25 (4.6) 0.83 (0.46–1.48)
) 28 (7.2) 0.32 (0.15–0.68)
) 23 (7.1) 0.62 (0.33–1.17)
) 77 (5.2) 0.61 (0.42–0.87)
) 2 (2.6) 0.57 (0.05–6.32)onda
ated
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Fondaparinux Versus Enoxaparin With GP IIb/IIIa July 28, 2009:468–76ere given at least 6 h before PCI (Fig. 3). There were
onsistent benefits in terms of major bleeding of fondapa-
inux compared with enoxaparin in the PCI population in
oth those pre-treated (minimum 6 h) and not pre-treated
ith thienopyridines (Fig. 3). The outcomes by loading
eath, MI, Refractory Ischemia, Major Bleeding, and Netlinical Outcome at 30 Days n Those Treated With Thi nopyridineTable 5 De th, MI, Refractory I chemia, Major Ble ding, and NClinical Outcome at 30 Days in Those Treated With Th
Outcome
Thienopyridine Use
(n)
Fondaparinux
n (%)
Death, MI, or refractory
ischemia
Yes (13,532) 586 (8.6)
No (6,545) 219 (6.7)
Death Yes (13,532) 178 (2.6)
No (6,545) 117 (3.6)
MI Yes (13,532) 291 (4.3)
No (6,545) 96 (3.0)
Major bleeding Yes (13,532) 229 (3.4)
No (6,545) 85 (2.6)
Net clinical outcome† Yes (13,532) 749 (11.0)
No (6,545) 277 (8.5)
Baseline Characteristics for Patients Treated WTable 4 Baseline Characteristics for Patient
Characteristic
Thie
(n
Geographic region
North America
Latin America
Western Europe
Eastern Europe
Australia
South Africa
Asia
Age (mean)
Age 75 yrs
Male sex
Prior MI
Diabetic
Prior coronary bypass surgery
Prior PCI
Troponin/CK-MB ULN 1
ST-segment depression 1 mm
Transient ST-segment elevation 2 mm
T-wave inversion (2 mm)
Medications after randomization
Aspirin 1
Beta-blocker 1
ACE inhibitor
Statin 1
Intravenous heparin
GP IIb/IIIa inhibitors
Revascularization during initial hospitalization
PCI
Coronary bypass surgery
Data are presented as n (%). *The p value refers to difference in use
Abbreviations as in Table 1.Interaction p value for unadjusted analysis. †Net clinical outcome is defined as composite of death, MI,
Abbreviations as in Table 2.ose of clopidogrel in PCI population are shown in Table 3,
hich shows that the vast majority of patients received a
00-mg loading dose of clopidogrel.
P IIb/IIIa inhibitors and thienopyridine use. For
atients treated with both GP IIb/IIIa inhibitors and
yridines
xaparin
n (%)
Unadjusted HR
(95% CI)
Adjusted HR
(95% CI)
Interaction
p Value*
6 (9.1) 0.94 (0.84–1.05) 0.94 (0.84–1.06) 0.61
8 (7.5) 0.89 (0.74–1.07) 0.87 (0.72–1.05)
8 (3.2) 0.81 (0.66–0.98) 0.79 (0.64–0.96) 0.59
4 (4.1) 0.88 (0.69–1.13) 0.84 (0.65–1.10)
5 (4.6) 0.94 (0.80–1.11) 0.95 (0.81–1.12) 0.85
6 (3.3) 0.91 (0.69–1.20) 0.92 (0.69–1.21)
0 (5.4) 0.62 (0.53–0.73) 0.62 (0.52–0.73) 0.92
5 (4.2) 0.63 (0.48–0.83) 0.62 (0.47–0.83)
2 (13.2) 0.82 (0.75–0.91) 0.82 (0.74–0.90) 0.78
7 (10.6) 0.80 (0.68–0.93) 0.78 (0.66–0.92)
nd Without Thienopyridinesated With and Without Thienopyridines
dine Use
,532)
No Thienopyridine Use
(n  6,545) p Value
(82) 379 (18) 0.001*
(74) 493 (26)
(80) 1,419 (20)
(45) 3,725 (55)
(63) 191 (37)
(19) 158 (81)
(88) 181 (12)
68 0.001
(24) 1,847 (28) 0.001
(65) 3,587 (55) 0.001
(25) 1,782 (27) 0.001
(25) 1,655 (25) 0.98
(9) 379 (6) 0.001
(14) 422 (6) 0.001
(74) 4,103 (63) 0.001
(49) 3,587 (55) 0.001
(7) 279 (4) 0.001
(24) 1,706 (26) 0.006
(98) 6,383 (98) 0.95
(88) 5,598 (86) 0.001
(69) 4,752 (73) 0.001
(83) 4,396 (67) 0.001
(16) 683 (10) 0.001
(24) 384 (6) 0.001
(49) 239 (4) 0.001
(8) 751 (11) 0.001
opyridines between the different geographic regions.set
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5,591
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8,792
3,382
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0,035
6,655
874
3,283
3,193
1,960
9,311
1,266
2,138
3,246
6,650
1,111refractory ischemia, or major bleeding.
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July 28, 2009:468–76 Fondaparinux Versus Enoxaparin With GP IIb/IIIahienopyridines, there were similar rates of death, MI,
nd refractory ischemia in both the fondaparinux and the
noxaparin groups (Fig. 1). There was a significant
eduction in the rates of major bleeding and net clinical
utcome with fondaparinux compared with enoxaparin in
hose treated with both agents during initial hospitaliza-
ion (Fig. 1). In those undergoing PCI during the initial
ospitalization, there was a significant reduction in major
leeding with fondaparinux regardless of whether pa-
ients received combined therapy with both GP IIb/IIIa
nhibitors and thienopyridine pre-treatment (at least 6 h
re-PCI) (Fig. 3).
iscussion
ur analysis shows that fondaparinux is associated with a
0% reduction in major bleeding compared with enoxaparin
hen used on top of background therapy with GP IIb/IIIa
nhibitors or thienopyridines. Ischemic outcomes were sim-
lar between the 2 groups, but fondaparinux was associated
ith superior net clinical outcomes. These data provide
upport for the efficacy and safety of fondaparinux use in
atients treated concurrently with GP IIb/IIIa inhibitors
nd thienopyridines.
Thienopyridines have been shown to reduce the compos-
te of death, MI, or stroke in patients with acute coronary
yndromes in the CURE (Clopidogrel in Unstable angina to
revent Recurrent Events) trial by 20% (relative risk [RR]:
.80, 95% CI: 0.72 to 0.90) but at the expense of an
ncreased risk of bleeding (RR: 1.38, 95% CI: 1.13 to 1.67)
1). Similarly, GP IIb/IIIa inhibitors have been shown to
ave a modest benefit with regard to death or MI in all
atients with acute coronary syndromes from a meta-
nalysis (odds ratio [OR]: 0.91, 95% CI: 0.85 to 0.99) but
t the expense of a 60% increase in the odds of bleeding
OR: 1.62, 95% CI: 1.36 to 1.94) (2).
Both thienopyridines and GP IIb/IIIa inhibitors were
ested on top of either enoxaparin or unfractionated heparin
n this analysis of the OASIS 5 study. Our study suggests
hat fondaparinux instead of enoxaparin can potentially
ffset the increased bleeding risk associated with thienopy-
idines and GP IIb/IIIa inhibitors, both agents recom-
ended as options in the current European and American
uidelines (3,4). In the ACUITY (Acute Catheterization
nd Urgent Intervention Triage Strategy) trial, bivalirudin
lone reduced major bleeding compared with unfractionated
eparin plus GP IIb/IIIa inhibitors (10). However, in this
rial, bivalirudin plus GP IIb/IIIa had similar rates of major
leeding compared with heparin plus GP IIb/IIIa. These
esults suggested that the increased risk of bleeding with GP
Ib/IIIa inhibitors was so significant that it seemed to
verwhelm the effect of different antithrombins in terms of
leeding. On the other hand, our analysis shows that in the
etting of GP IIb/IIIa use, the choice of antithrombin agents important and fondaparinux can reduce bleeding events
ompared with enoxaparin in this setting.
A number of studies (5–7) have shown a marked in-
reased risk in death associated with major bleeding. In an
nalysis of over 34,000 patients with acute coronary syn-
romes, major bleeding was associated with not only a
-fold increase in mortality but also a 4-fold increase in MI
fter adjusting for covariates (5). With increased use of
hienopyridines and GP IIb/IIIa inhibitors, the bleeding
isk associated with combining these agents with different
ntithrombotic medications is an important issue in the
herapy of NSTE-ACS.
The safety and efficacy of enoxaparin compared with
nfractionated heparin with frequent use of GP IIb/IIIa
nhibitors use was assessed in the SYNERGY (Superior
ield of the New strategy of Enoxaparin, Revascularization,
nd GlYcoprotein inhibitors) trial (11). In over 10,000
atients with NSTE-ACS, enoxaparin was associated with
20% increase in risk of major bleeding compared with
nfractionated heparin (11). The finding of an increased
isk of bleeding with enoxaparin in the setting of potent
ntiplatelet therapy is consistent with our findings.
tudy limitations. The main limitation of this study is that
t is based on a post-randomization subgroup and the results
ay have been influenced by potential confounding vari-
bles. To partially offset this, we extensively adjusted both
he efficacy and the safety results with a propensity analysis.
n addition, these subgroup results are consistent with the
esults of the overall trial.
onclusions
ondaparinux had a superior net efficacy to safety balance
ompared with enoxaparin in those treated with either GP
Ib/IIIa inhibitors or thienopyridines. In the setting of GP
Ib/IIIa inhibitors, fondaparinux is the only agent compared
ith enoxaparin that has been shown to have a superior net
fficacy to safety balance.
eprint requests and correspondence: Dr. Sanjit S. Jolly, Mc-
aster Clinic Room 630, Hamilton General Hospital, 237 Barton
treet East, Hamilton, Ontario L8L 2X2, Canada. E-mail:
ollyss@mcmaster.ca.
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